EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 13-Oct-2025 08:11 ET (13-Oct-2025 12:11 GMT/UTC)

7-Sep-2025

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

International Association for the Study of Lung Cancer
Reports and Proceedings

New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations.

6-Sep-2025

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

International Association for the Study of Lung Cancer
Reports and Proceedings

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

6-Sep-2025

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

International Association for the Study of Lung Cancer
Reports and Proceedings

A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

This study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

6-Sep-2025

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

International Association for the Study of Lung Cancer
Reports and Proceedings

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

6-Sep-2025

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

International Association for the Study of Lung Cancer
Reports and Proceedings

An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease. These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

6-Sep-2025

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

International Association for the Study of Lung Cancer
Reports and Proceedings

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.

5-Sep-2025

Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor

Pennington Biomedical Research Center
Business Announcement

Pennington Biomedical Research Center is proud to announce that Dr. Steven B. Heymsfield, Professor of Metabolism and Body Composition, has been named a Boyd Professor of Louisiana State University – the highest faculty rank and honor awarded within the LSU System.

5-Sep-2025

New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment

Compuscript Ltd
Peer-Reviewed Publication

Head and neck cancer remains a major global health challenge, ranking among the six most common cancers worldwide and claiming hundreds of thousands of lives each year. A growing body of evidence now points to an intricate connection between energy metabolism and immune regulation as a driving force behind the onset, progression, and treatment resistance of these cancers. The latest comprehensive review on this topic underscores the potential of targeting these intertwined processes to unlock more effective therapies.

Journal: Genes & Diseases

5-Sep-2025

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

Compuscript Ltd
Peer-Reviewed Publication

The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively infect and destroy tumor cells, while simultaneously stimulating anti-tumor immune responses. The latest advancements in genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced patient quality of life.

Journal: Genes & Diseases

5-Sep-2025

Natural medicines target tumor vascular microenvironment to inhibit cancer growth

Compuscript Ltd
Peer-Reviewed Publication

Recent advances in cancer treatment highlight the potential of natural medicines to target the tumor vascular microenvironment, offering a novel strategy to inhibit tumor growth and metastasis. Unlike conventional therapies that directly target tumor cells, natural compounds focus on normalizing tumor vasculature and inhibiting pathological angiogenesis, crucial processes in cancer progression. This innovative approach holds promise in enhancing anti-cancer therapies while minimizing side effects.

Journal: Genes & Diseases